Clinical trial · Observational
A Retrospective Study of Patients With Leukemia Relapse in the CNS Treated With CAR T Cells
CARs for CNS-Leukemia Relapse: A Retrospective International Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
CAR T cells targeting CD19 have been approved for patients with relapsed or refractory ALL, failing two or more prior protocols. Several institutional-based studies with other CAR T cells targeting CD19 have demonstrated outstanding response rates in patients with refractory disease, and the ability of CAR T cells to clear CNS leukemia. Nevertheless, these cases are sparse and have never been reported collectively. Here, we aim to retrospectively assess toxicity and long term outcome of patients treated with CAR T cells for CNS relapse of ALL.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- CNS ALL at lymphodepletion
- description
- Patients with active CNS leukemia at the time of lymphodepletion
- label
- CNS ALL at inclusion
- description
- Patients who were referred to CAR T-cells with CNS disease, which was cleared by the time of lymphodepletion
Primary outcomes (1)
- measure
- Overall survival
- timeFrame
- 6 months
- description
- Duration between CAR T-cell infusion and death or last follow-up, according to Kaplan-Meier analysis
Secondary outcomes (3)
- measure
- Incidence of CAR-related CRS or ICANS per ASCTC guidelines
- timeFrame
- 2 months
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Prior diagnosis of B-cell acute lymphoblastic leukemia involving the central nervous system * Treatment with CAR T cells (either on a clinical trial or commercial use) due to this indication
References
Publications (0)
Data not yet available